How many clinical trials are tracked for Cachexia?

15 trials are tracked, 3 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Ophthalmology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

Cachexia

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cachexia

15 trials tracked for Cachexia: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 632 citations.

15Trials tracked

3Phase 3 & 4

0Recruiting

3With published results

Phase distribution

Phase 3 3 Phase 2 7 Phase 1 3 Other / NA 2

Phase 3 Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2) Completed · 632 cited
Phase 3 Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1) Completed · 631 cited
Phase 3 Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3) Completed · 179 cited
Phase 2 Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss Completed
Phase 2 Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD) Completed
Phase 2 Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 Completed

Show 9 more trials

Phase 2 Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas Completed
Phase 2 SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD) Completed
Phase 2 Regimen for the Treatment of Cachexia in Subjects With NSCLC Completed
Phase 2 Study of GTx-024 on Muscle Wasting (Cachexia) Cancer. Completed
Phase 1 Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia Completed
Phase 1 Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. Completed
Phase 1 Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma Completed
N/A Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer. Completed
N/A Electronic-health Application To Measure Outcomes REmotely Clinical Trial Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Cachexia: what the trials found

Anamorelin HCl has demonstrated significant improvements in lean body mass and A/CS domain scores in patients with cachexia [1, 2]. Specifically, trials showed a change in lean body mass of 0.99 and 0.65 respectively (p<0.0001) and A/CS domain score improvements of 4.12 and 3.48 (p=0.0004; p=0.0016) [1, 2]. One study also reported a change in A/CS domain scores of 4.46 vs 3.24 ³.

In early-phase studies for PF-06946860, patients showed changes in appetite scores at week 4 (2.45; 1.84) and across multiple weeks (ranging from 0.99 to 2.30) ¹¹. Fatigue scores were also recorded over a 6-week period following administration ¹¹.

Recent results — preliminary, needs further review

* Ponsegromab showed no significant change in physical activity or mean activity level during maximum 6 minutes at week 12 (p=0.8260; p=0.5762) ⁴. * SUN11031 was associated with changes in lean body mass of 37.85 to 40.39 across various time points in patients with COPD-associated cachexia ⁵. * BYM338 showed a 4.97% increase in total lean body mass (LBM) via DXA at week 8 compared to 2.41% for placebo ⁸. * Placebo Testosterone was associated with changes in total lean body mass of -3.31 vs 1.42 and improvements in peak isometric leg strength ¹³. * In-person nutritional counseling by a registered dietitian resulted in estimated mean weight changes of -0.1, -0.2, and -1.2 over 6 months ¹⁴.

For the clinician treating this condition

Anamorelin HCl is associated with statistically significant increases in lean body mass and improvements in A/CS domain scores [1, 2].
PF-06946860 has been shown to impact appetite scores in patients with cancer-related cachexia ¹¹.

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.